$0.46
3.40% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US0198181036
Symbol
ALVR
Sector
Industry

AlloVir Inc Stock price

$0.46
-0.08 15.50% 1M
-0.32 41.41% 6M
-0.22 32.77% YTD
-0.24 34.63% 1Y
-12.97 96.60% 3Y
-24.93 98.20% 5Y
-24.93 98.20% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.02 3.40%
ISIN
US0198181036
Symbol
ALVR
Sector
Industry

Key metrics

Market capitalization $52.81m
Enterprise Value $-69.04m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.73
P/B ratio (TTM) P/B ratio 0.44
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-79.57m
Free Cash Flow (TTM) Free Cash Flow $-94.87m
Cash position $121.85m
EPS (TTM) EPS $-0.88
P/E forward negative
Short interest 7.85%
Show more

Is AlloVir Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

AlloVir Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast AlloVir Inc:

1x Sell
100%

Analyst Opinions

1 Analyst has issued a forecast AlloVir Inc:

Sell
100%

Financial data from AlloVir Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.14 0.14
97% 97%
-
-0.14 -0.14
-
-
- Selling and Administrative Expenses 34 34
32% 32%
-
- Research and Development Expense 45 45
63% 63%
-
-79 -79
54% 54%
-
- Depreciation and Amortization 0.14 0.14
-
-
EBIT (Operating Income) EBIT -80 -80
55% 55%
-
Net Profit -100 -100
41% 41%
-

In millions USD.

Don't miss a Thing! We will send you all news about AlloVir Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AlloVir Inc Stock News

Neutral
Business Wire
about 2 months ago
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of AlloVir, Inc. (the “Company”) (NasdaqCM: ALVR) and Kalaris Therapeutics. Pursuant to the terms of the agreement, upon completion of the Merger, pre-Merger AlloVir stockholders are expected to own approximately 2...
Neutral
GlobeNewsWire
about 2 months ago
NEW YORK, Nov. 09, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Neutral
PRNewsWire
about 2 months ago
NEW YORK , Nov. 8, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: EMCORE Corporation (NASDAQ: EMKR)'s sale to Velocity One for $3.10 per share in cash. If you are an EMCORE shareholder, click here to learn more abo...
More AlloVir Inc News

Company Profile

AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John Wilson, and Ann M. Leen in 2013 and is headquartered in Houston, TX.

Head office United States
CEO Vikas Sinha
Employees 112
Founded 2013
Website www.allovir.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today